BRPI0419067A - método para aumento da cognição utilizando ziprasidona - Google Patents
método para aumento da cognição utilizando ziprasidonaInfo
- Publication number
- BRPI0419067A BRPI0419067A BRPI0419067-0A BRPI0419067A BRPI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- ziprasidone
- formula
- compound
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 5
- 229960000607 ziprasidone Drugs 0.000 title abstract 5
- 230000019771 cognition Effects 0.000 title abstract 3
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 206010003805 Autism Diseases 0.000 abstract 2
- 208000020706 Autistic disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 208000036626 Mental retardation Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000009329 sexual behaviour Effects 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010019191 Head banging Diseases 0.000 abstract 1
- 206010022524 Intentional self-injury Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000005560 Self Mutilation Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- -1 piperazinyl heterocyclic compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000013623 stereotypic movement disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47137903P | 2003-05-16 | 2003-05-16 | |
| PCT/IB2004/001600 WO2004100956A1 (en) | 2003-05-16 | 2004-05-05 | Method for enhancing cognition using ziprasidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0419067A true BRPI0419067A (pt) | 2007-12-11 |
Family
ID=33452442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0419067-0A BRPI0419067A (pt) | 2003-05-16 | 2004-05-05 | método para aumento da cognição utilizando ziprasidona |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050014764A1 (https=) |
| EP (1) | EP1626722A1 (https=) |
| JP (1) | JP2006528236A (https=) |
| AR (1) | AR044337A1 (https=) |
| BR (1) | BRPI0419067A (https=) |
| CA (2) | CA2625837A1 (https=) |
| MX (1) | MXPA05012325A (https=) |
| TW (1) | TW200507847A (https=) |
| WO (1) | WO2004100956A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| EP1617832B1 (en) | 2003-04-29 | 2008-03-12 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| US20100222353A1 (en) * | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| EP2520567A3 (en) * | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| JP2010506853A (ja) * | 2006-10-12 | 2010-03-04 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 疼痛などのナトリウムチャネル媒介性の疾患の処置のための、スピロ（［３，２−フロ］ピリジン−３，３’−インドール）−２’（１’ｈ）−オン誘導体および関連化合物 |
| AR063280A1 (es) * | 2006-10-12 | 2009-01-21 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos |
| AU2007307635A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| KR20100045983A (ko) * | 2007-06-29 | 2010-05-04 | 에모리 유니버시티 | 신경보호를 위한 ｎｍｄａ 수용체 길항물질 |
| NZ589764A (en) * | 2008-05-09 | 2012-10-26 | Univ Emory | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| CA2741024A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CN105218565A (zh) | 2008-10-17 | 2016-01-06 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| MX2012004373A (es) * | 2009-10-14 | 2012-06-28 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol. |
| MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
| CA2788440A1 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| CA2799154A1 (en) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Indazole inhibitors of kinase |
| CN110893181A (zh) | 2012-06-06 | 2020-03-20 | 纳丙药业有限责任公司 | 治疗超重和肥胖症的方法 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| WO2016191316A1 (en) * | 2015-05-22 | 2016-12-01 | Stem Cell Theranostics, Inc. | Modulation of drug-induced cardiotoxicity |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US6110918A (en) * | 1996-05-07 | 2000-08-29 | Pfizer Inc | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| WO2000059459A1 (en) * | 1999-03-30 | 2000-10-12 | Lion Corporation | Hairdye composition of single preparation type containing an oxidase |
| WO2000059489A2 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
-
2004
- 2004-05-05 EP EP04731234A patent/EP1626722A1/en not_active Withdrawn
- 2004-05-05 CA CA002625837A patent/CA2625837A1/en not_active Abandoned
- 2004-05-05 CA CA002525323A patent/CA2525323A1/en not_active Abandoned
- 2004-05-05 MX MXPA05012325A patent/MXPA05012325A/es unknown
- 2004-05-05 BR BRPI0419067-0A patent/BRPI0419067A/pt not_active IP Right Cessation
- 2004-05-05 JP JP2006530660A patent/JP2006528236A/ja active Pending
- 2004-05-05 WO PCT/IB2004/001600 patent/WO2004100956A1/en not_active Ceased
- 2004-05-14 AR ARP040101652A patent/AR044337A1/es unknown
- 2004-05-14 TW TW093113727A patent/TW200507847A/zh unknown
- 2004-05-14 US US10/846,797 patent/US20050014764A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/110,522 patent/US20080269246A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2625837A1 (en) | 2004-11-25 |
| US20050014764A1 (en) | 2005-01-20 |
| EP1626722A1 (en) | 2006-02-22 |
| AR044337A1 (es) | 2005-09-07 |
| US20080269246A1 (en) | 2008-10-30 |
| WO2004100956A1 (en) | 2004-11-25 |
| MXPA05012325A (es) | 2006-01-30 |
| CA2525323A1 (en) | 2004-11-25 |
| JP2006528236A (ja) | 2006-12-14 |
| TW200507847A (en) | 2005-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0419067A (pt) | método para aumento da cognição utilizando ziprasidona | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| TN2009000242A1 (en) | Sulfonyl-phenyl-2h-[1,2,4]oxodiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals | |
| TNSN08145A1 (en) | Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | |
| BRPI0518798A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodos para tratar diabete tipo ii e para tratar uma condiÇço ou distérbio | |
| MA34922B1 (fr) | Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques | |
| BR0312999A (pt) | Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente | |
| EA200602191A1 (ru) | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения | |
| EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
| MA33119B1 (fr) | Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase | |
| BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
| BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
| MA32108B1 (fr) | Derives d'indazole | |
| BRPI0411098A (pt) | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos | |
| MA30592B1 (fr) | Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques | |
| BR0011403A (pt) | Processos para a purificação e para a preparação de ácido acrìlico ou ácido metacrìlico | |
| EA200700909A1 (ru) | Азаиндолкарбоксамиды | |
| EA200800303A1 (ru) | Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами | |
| BRPI0713381A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de uma doença | |
| BRPI0410222A (pt) | tratamento de distúrbios bipolares e sintomas associados | |
| BRPI0509512A (pt) | método de tratar esquizofrenia e/ou anormalidades glicorregulatórias | |
| TW200508210A (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
| BRPI0514419A (pt) | amidas do ácido tienopirrol carboxìlico substituìdas, amidas do ácido pirrolotiazol carboxìlico, e análogos relacionados como inibidores de caseìna cinase iépsilon, bem como composição farmacêutica e processo para a preparação dos mesmos | |
| TW200621732A (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
| EA202191521A1 (ru) | 2-фторированные желчные кислоты для лечения нейродегенеративных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 3A. E 6A. ANUIDADES. |
|
| B08J | Incorrect entry in the gazette republished [chapter 8.10 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2082 DE 30/11/2010. TEXTO CORRETO: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2082 DE 30/11/2010 E RPI 2090 DE 25/01/2011. |